Medchem (P.R.), Inc. v. Commissioner

295 F.3d 118, 2002 U.S. App. LEXIS 13831, 2002 WL 1448841
CourtCourt of Appeals for the First Circuit
DecidedJuly 10, 2002
Docket01-2251
StatusPublished
Cited by15 cases

This text of 295 F.3d 118 (Medchem (P.R.), Inc. v. Commissioner) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Medchem (P.R.), Inc. v. Commissioner, 295 F.3d 118, 2002 U.S. App. LEXIS 13831, 2002 WL 1448841 (1st Cir. 2002).

Opinion

LYNCH, Circuit Judge.

This tax case requires interpretation of the Internal Revenue Code’s Puerto Rico and Possession Tax Credit provision, 26 U.S.C. § 936 (2000), which permits a domestic corporation to elect a possession tax credit if it meets certain conditions, id. § 936(a). The condition on which this case turns is that 75% or more of the gross income of the corporation for the three preceding years must be “derived from the active conduct of a trade or business within a possession of the United States.” Id. § 936(a)(2)(B). 1

The taxpayer, MedChem (P.R.), Inc. (“M-PR”), contends that it meets this “active conduct of a trade or business” requirement; the Tax Court and the Commissioner of Internal Revenue disagree. This issue appears to be one of first impression at the circuit level.

The particular tax credit codified at § 936 was added by the Tax Reform Act of 1976, Pub.L. No. 94-455, 90 Stat. 1520 (1976) (codified in scattered sections of 26 U.S.C.), although it has its roots in legislation from the 1920s, see Revenue Act of 1921, Pub.L. No. 67-98, § 262, 42 Stat. 227, 271 (1921). The government tells us that the tax credit is in the process of being phased out. See 26 U.S.C. § 936(j). This case has, in the interim, consequences for domestic corporations involved in business activity in Puerto Rico 2 and certain other possessions. Unfortunately, there are no promulgated regulations under § 936(a) and domestic corporations have been forced to make business arrangements in U.S. possessions without the pri- or guidance such regulations might provide.

Based primarily on § 936’s text, understood in the context of the legislative history, we conclude that M-PR has failed to meet the “active conduct of a trade or business” requirement and, accordingly, we affirm the Tax Court’s judgment. We do so without adopting the Tax Court’s *120 proposed test for what constitutes the active conduct of a trade or business in a U.S. possession for purposes of § 936(a).

I.

The facts in this case are not in dispute, Medchem (P.R.), Inc. v. Comm’r, 116 T.C. 308, 310, 2001 WL 530695 (2001); see generally Tax Ct. R. 122, although M-PR contests the inferences the Tax Court drew from the stipulated record. M-PR is the taxpayer claiming to qualify for the possessions tax credit.

M-PR’s identity has gone through several transformations. M-PR was incorporated in Delaware on December 8, 1987, as MedChem Puerto Rico, Inc. A couple of weeks later, on December 22, MedChem Puerto Rico, Inc. changed its name to Bio-Chem Products, Inc. Then, on March 1, 1992, BioChem Products, Inc. changed its state of incorporation to Massachusetts and, on November 25, 1992, changed its name to MedChem P.R., Inc. M-PR and all of its predecessors — all of which we will refer to as M-PR — were at all times wholly owned subsidiaries of MedChem Products, Inc. (“M-USA”). M-USA is a Massachusetts corporation with its principal place of business in Woburn, Massachusetts. Following the tax years at issue in this case, 3 M-USA succeeded M-PR through a merger of M-PR into M-USA.

The IRS found a deficiency of $815,196 4 in M-PR’s federal income tax paid for the tax year ending August 31, 1992, and a deficiency of $1,705,019 in M-USA’s tax payments for the same period. In consolidated cases in the Tax Court, M-USA, as successor by merger to M-PR, contested both of these claims of deficiency. Med-chem, 116 T.C. at 309. It is the $815,196 liability that is at issue here.

During the relevant three-year period— that is, during each of M-PR’s taxable years ending on August 31, 1990-92 — all of M-PR’s reported income was “intangible property income,” see 26 U.S.C. § 936(h)(3), attributable to the sale of Avi-tene, a blood-clotting drug manufactured by Alcon Puerto Rico, Inc. (“A-PR”), an unrelated company.

On December 18, 1987, ten days after M-PR was incorporated, A-PR along with Alcon Pharmaceuticals, Ltd. and Alcon Laboratories, Inc. (collectively “Alcon entities”) sold the Avitene portion of their business to M-PR and M-USA. The Alcon entities sold the equipment, raw materials, technology, and other assets associated with Avitene’s manufacturing. M-USA acquired the receivables, non-competition agreements, goodwill, contract rights, records, patents and related know-how, trademarks, and Food and Drug Administration approvals. M-PR acquired receivables, inventory, and title to the machinery and equipment located within A-PR’s manufacturing facility in Humacao, Puerto Rico. Those assets did not include A-PR’s Avi-tene manufacturing facility in Humacao.

Before the acquisition, A-PR had been the manufacturer of Avitene. M-USA had nothing to do with the drug. Until ten days prior to the acquisition, M-PR did *121 not exist. As part of the sale, A-PR agreed to continue manufacturing Avitene for M-PR using A-PR’s own facility and labor and M-PR’s recently-acquired raw materials and equipment. A-PR also used the technology acquired by M-USA. MPR held title to the in-process and finished Avitene. A-PR shipped finished Avitene from its facility to M-USA, and title passed to M-USA, the purchaser. A-PR was solely responsible for any issues that arose until the finished product was delivered to a carrier for shipment to M-USA. In return, A-PR sent its invoices for its manufacturing services directly to M-USA, which paid, from M-PR’s account, a price equal to the manufacturing cost plus 10%. The primary change effected by the 1987 sale was that certain assets were held in the name of either M-PR or its parent, M-USA.

The reason M-PR entered into the processing agreement with A-PR, in which APR manufactured Avitene for M-PR using M-PR’s raw materials and equipment, was that M-PR needed to ensure a steady supply of Avitene until it built its own manufacturing facility in Puerto Rico. As it turns out, M-PR later abandoned its plan to construct its own Avitene facility in Puerto Rico.

During much of the relevant three-year period, M-PR had no employees. Its one employee, Mr. Perez, was a former A-PR employee. He worked for M-PR from March 1988 to June 1990 out of a one-room office that M-PR maintained. Mr. Perez spent much of his time planning M-PR’s transition to its own Avitene manufacturing facility. M-PR also paid three independent contractors to assist Mr. Perez. M-PR treated the independent contractors as nonemployees for payroll and tax purposes. M-USA and A-PR employed the individuals, other than Mr. Perez and the independent contractors, associated with the Avitene manufacturing and sales business.

At the time of the 1987 processing agreement, M-PR and M-USA had hoped to establish their own manufacturing facility in Puerto Rico.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Pacheco
D. Puerto Rico, 2024
James Goggin v. State Tax Assessor
2018 ME 111 (Supreme Judicial Court of Maine, 2018)
Robb Evans & Associates, LLC v. United States
850 F.3d 24 (First Circuit, 2017)
Geosyntec Consultants, Inc. v. United States
776 F.3d 1330 (Eleventh Circuit, 2015)
Free-Pacheco v. United States
117 Fed. Cl. 228 (Federal Claims, 2014)
OMJ Pharmaceuticals, Inc. v. United States
753 F.3d 333 (First Circuit, 2014)
Advo, Inc. & Subsidiaries v. Commissioner
141 T.C. No. 9 (U.S. Tax Court, 2013)
Clearmeadow Investments, LLC v. United States
87 Fed. Cl. 509 (Federal Claims, 2009)
Textron Inc. v. Commissioner of IRS
336 F.3d 26 (First Circuit, 2003)
Haffner's Service Stations, Inc. v. Commissioner
326 F.3d 1 (First Circuit, 2003)
Interex, Inc. v. Commissioner of
321 F.3d 55 (First Circuit, 2003)
Capital Video Corp. v. Commissioner
311 F.3d 458 (First Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
295 F.3d 118, 2002 U.S. App. LEXIS 13831, 2002 WL 1448841, Counsel Stack Legal Research, https://law.counselstack.com/opinion/medchem-pr-inc-v-commissioner-ca1-2002.